GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2010” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2010. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days.

SWOT Analysis report provides you a strategic analysis and detailed overview of the company’s businesses and operations.

In this report, our analysts reveal the company’s business strategy, strengths, weakness, opportunities and threats and detailed information such as :
- Key events associated with the company,
- Major products, services and brands of the company,
- Key competitors,
- Key executives, biographies and employment history,
- Personnel heading key departments and functions,
- Important locations and subsidiaries
- Financial analysis and ratios based on the annual financial statements published by the company including a 5 years history.
- Interim ratios for the last five interim periods

You get also in deepth information about operations to identify potential customers, partners and suppliers. business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.



Latest Company Developments:

Table Of Contents

1 Table of Contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 6

II Deal Summary 8
II. 1 Pharmaceuticals and Healthcare, World Deals Analysis, Q3 2010 8
II. 2 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Value, Q3 2010 10
II. 3 Pharmaceuticals and Healthcare, Global, Top Deals, Q3 2010 11
II. 3.1 Reckitt Benckiser To Take Over SSL 11
II. 3.2 Carlyle Group Completes Acquisition Of NBTY 11
II. 3.3 Johnson and Johnson To Take Over Additional Stake In Crucell 11
II. 3.4 Covance Concludes a New Deal With Sanofi-Aventis 12
II. 3.5 Gilead Sciences Completes Private Placement Of Senior Notes For US$ 2,200 Mln 12

III Pharmaceuticals and Healthcare, Merger and Acquisition Deal Summary, by Type 13
III. 1 Pharmaceuticals and Healthcare, Global, Merger and Acquisition, Q3 2010 13
III. 1.1 Top Merger and Acquisition Deals in Q3 2010 14
III. 1.2 Pharmaceuticals and Healthcare, World MandA Deals, by Therapy Area, Q3 2009 - Q3 2010 15
III. 2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Q3 2010 16
III. 2.1 Top Initial Public Offerings in Q3 2010 17
III. 2.2 Top Secondary Offerings in Q3 2010 17
III. 2.3 Top PIPE Deals in Q3 2010 17
III. 2.4 Pharmaceuticals and Healthcare, Global, IPO deals, Q4 2009 - Q3 2010 18
III. 2.5 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2009 - Q3 2010 19
III. 3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Q3 2010 20
III. 3.1 Top Public Debt Offerings in Q3 2010 21
III. 3.2 Top Private Debt Placements in Q3 2010 21
III. 3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, Q3 2009 - Q3 2010 22
III. 4 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, Q3 2010 23
III. 4.1 Top Venture Financing Deals in Q3 2010 24
III. 4.2 Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2010 25
III. 4.3 Pharmaceuticals and Healthcare, Global, Venture Capital, by Therapy Area, Q3 2009 - Q3 2010 26
III. 4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Q4 2009 - Q3 2010 27
III. 4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Firms, Q3 2010 28
III. 5 Pharmaceuticals and Healthcare, World Private Equity Deals, Q3 2010 29
III. 5.1 Top Private Equity Deals in Q3 2010 30
III. 5.2 Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2009 - Q3 2010 31

IV Pharmaceuticals and Healthcare, Global, Partnership Deals, Q3 2010 32
IV. 1 Pharmaceuticals and Healthcare, Global, Partnership Deals, Q3 2010 32
IV. 2 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2009 - Q3 2010 33
IV. 3 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2010 34
IV. 3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Deal Value, Q3 2010 35
IV. 3.2 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2010 35
IV. 3.3 Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2010 36
IV. 4 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
IV. 5 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 38
IV. 6 Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39

V Pharmaceuticals and Healthcare, Global, Licensing Agreements, Q3 2010 40
V. 1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, Q3 2010 40
V. 2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
V. 2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2010 42
V. 2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, Q3 2010 42
V. 2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2010 43
V. 2.4 Pharmaceuticals and Healthcare, Global, Licensing Agreements with Equity Investment, Q3 2009 - Q3 2010 43
V. 3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2009 - Q3 2010 44
V. 4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 45
V. 5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Value (US$ m), Q3 2009 - Q3 2010 46
V. 6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 47

VI Deal Summary by Therapy Area 48
VI. 1 Pharmaceuticals and Healthcare, Oncology Deals, Q3 2010 48
VI. 1.1 Oncology - Deals of the Quarter 49
VI. 2 Pharmaceuticals and Healthcare, Central Nervous System Deals, Q3 2010 50
VI. 2.1 Central Nervous System - Deals of the Quarter 51
VI. 3 Pharmaceuticals and Healthcare, Infectious Disease Deals, Q3 2010 52
VI. 3.1 Infectious Disease - Deals of the Quarter 53
VI. 4 Pharmaceuticals and Healthcare, Immunology Deals, Q3 2010 54
VI. 4.1 Immunology - Deals of the Quarter 55
VI. 5 Pharmaceuticals and Healthcare, Cardiovascular Deals, Q3 2010 56
VI. 5.1 Cardiovascular - Deals of the Quarter 57
VI. 6 Pharmaceuticals and Healthcare, Metabolic Disorders Deals, Q3 2010 58
VI. 6.1 Metabolic Disorders - Deals of the Quarter 59
VI. 7 Pharmaceuticals and Healthcare, Musculoskeletal Deals, Q3 2010 60
VI. 7.1 Musculoskeletal - Deals of the Quarter 61
VI. 8 Pharmaceuticals and Healthcare, Respiratory Deals, Q3 2010 62
VI. 8.1 Respiratory - Deals of the Quarter 63
VI. 9 Pharmaceuticals and Healthcare, Gastrointestinal Deals, Q3 2010 64
VI. 9.1 Gastrointestinal - Deals of the Quarter 65
VI. 10 Pharmaceuticals and Healthcare, Dermatology Deals, Q3 2010 66
VI. 10.1 Dermatology - Deals of the Quarter 67

VII Deal Summary by Geography 68
VII. 1 Pharmaceuticals and Healthcare, North America Region Deals, Q3 2010 68
VII. 1.1 North America - Deals of the Quarter 69
VII. 2 Pharmaceuticals and Healthcare, Europe Region Deals, Q3 2010 70
VII. 2.1 Europe - Deals of the Quarter 71
VII. 3 Pharmaceuticals and Healthcare, Asia-Pacific Deals, Q3 2010 72
VII. 3.1 Asia-Pacific - Deals of the Quarter 73
VII. 4 Pharmaceuticals and Healthcare, Rest of the World Deals, Q3 2010 74
VII. 4.1 Rest of the World - Deals of the Quarter 75

VIII Pharmaceuticals and Healthcare, Top Advisors 76
VIII. 1 Pharmaceuticals and Healthcare, World Top Financial Advisors, Merger and Acquisition, Q4 2009 - Q3 2010 76
VIII. 2 Pharmaceuticals and Healthcare, Top Financial Advisors, Equity Offerings, Q4 2009 - Q3 2010 77

IX Further Information 78
IX. 1 Methodology 78
IX. 2 About GlobalData 78
IX. 3 Contact Us 79
IX. 4 Disclosure information 79
IX. 5 Disclaimer 79
1.1 List of Data tables
Data table 1: Pharmaceuticals and Healthcare, Global, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 9
Data table 2: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Value (%), Q3 2010 10
Data table 3: Pharmaceuticals and Healthcare, Global, Top Deals, Q3 2010 11
Data table 4: Pharmaceuticals and Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 13
Data table 5: Pharmaceuticals and Healthcare, Global, Top Merger and Acquisition Deals, Q3 2010 14
Data table 6: Pharmaceuticals and Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), by Therapy Area,, Q3 2009 - Q3 2010 15
Data table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 16
Data table 8: Pharmaceuticals and Healthcare, Global, Top Initial Public Offering Deals, Q3 2010 17
Data table 9: Pharmaceuticals and Healthcare, Global, Top Secondary Offering Deals, Q3 2010 17
Data table 10: Pharmaceuticals and Healthcare, Global, Top PIPE Deals, Q3 2010 17
Data table 11: Pharmaceuticals and Healthcare, Global, IPO Deals, Q4 2009 - Q3 2010 18
Data table 12: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$m),, Q3 2009 - Q3 2010 19
Data table 13: Pharmaceuticals and Healthcare, Global, Debt Offering, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 20
Data table 14: Medical Equipment, Global, Top Public Debt Offerings, Q3 2010 21
Data table 15: Medical Equipment, Global, Top Private Debt Placements, Q3 2010 21
Data table 16: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 22
Data table 17: Pharmaceuticals and Healthcare, Global, Venture Capital, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 23
Data table 18: Pharmaceuticals and Healthcare, Global, Top Venture Capital Deals, Q3 2010 24
Data table 19: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Value (%), Q3 2010 25
Data table 20: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Merger and Acquisition Deal Summary, Q3 2009 - Q3 2010 26
Data table 21: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 27
Data table 22: Pharmaceuticals and Healthcare, Global, Top VC Backed Firms, April il 2010 - September tember 2010 28
Data table 23: Pharmaceuticals and Healthcare, Global, Private Equity, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 29
Data table 24: Pharmaceuticals and Healthcare, Global, Top Private Equity Deals, Q3 2010 30
Data table 25: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Merger and Acquisition Deal Summary, Q3 2009 - Q3 2010 31
Data table 26: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 32
Data table 27: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 33
Data table 28: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 34
Data table 29: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2010 35
Data table 30: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2010 35
Data table 31: Pharmaceuticals and Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2010 36
Data table 32: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
Data table 33: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 38
Data table 34: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39
Data table 35: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 40
Data table 36: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Merger and Acquisition Deal Summary, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
Data table 37: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Deal Value, Q3 2010 42
Data table 38: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2010 42
Data table 39: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2010 43
Data table 40: Pharmaceuticals and Healthcare, Global, Licensing Agreements with Equity Investment, Q3 2009 - Q3 2010 43
Data table 41: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 44
Data table 42: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment (US$ m), Q3 2009 - Q3 2010 45
Data table 43: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 46
Data table 44: Pharmaceuticals and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 47
Data table 45: Pharmaceuticals and Healthcare, Global, Oncology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 49
Data table 46: Pharmaceuticals and Healthcare, Global, Central Nervous System, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 51
Data table 47: Pharmaceuticals and Healthcare, Global, Infectious Disease, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 53
Data table 48: Pharmaceuticals and Healthcare, Global, Immunology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 55
Data table 49: Pharmaceuticals and Healthcare, Global, Cardiovascular, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 57
Data table 50: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 59
Data table 51: Pharmaceuticals and Healthcare, Global, Musculoskeletal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 61
Data table 52: Pharmaceuticals and Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 63
Data table 53: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 64
Data table 54: Pharmaceuticals and Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 66
Data table 55: Pharmaceuticals and Healthcare, North America, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 69
Data table 56: Pharmaceuticals and Healthcare, Europe, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 71
Data table 57: Pharmaceuticals and Healthcare, Asia-Pacific, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 73
Data table 58: Pharmaceuticals and Healthcare, Rest of the World, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 74
Data table 59: Pharmaceuticals and Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Value (US$ m), Q4 2009 - Q3 2010 76
Data table 60: Pharmaceuticals and Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q3 2010 77
1.2 List of Charts
Chart 1: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 8
Chart 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Value (%), Q3 2010 10
Chart 3: Pharmaceuticals and Healthcare, Global, Merger and Acquisition, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 13
Chart 4: Pharmaceuticals and Healthcare, Global, Merger and Acquisition, by Therapy Area, Number of Deals and Deal Value (US$m), by Therapy Area, Q3 2009 - Q3 2010 15
Chart 5: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 16
Chart 6: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$m),, Q3 2009 - Q3 2010 19
Chart 7: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 20
Chart 8: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$ m),, Q3 2009 - Q3 2010 22
Chart 9: Pharmaceuticals and Healthcare, Global, Venture Capital, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 23
Chart 10: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Value (%), Q3 2010 25
Chart 11: Pharmaceuticals and Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q3 2009 - Q3 2010 26
Chart 12: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q4 2009 - Q3 2010 27
Chart 13: Pharmaceuticals and Healthcare, Global, Private Equity, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 29
Chart 14: Pharmaceuticals and Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q3 2009 - Q3 2010 31
Chart 15: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 32
Chart 16: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 33
Chart 17: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 34
Chart 18: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
Chart 19: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 38
Chart 20: Pharmaceuticals and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39
Chart 21: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 40
Chart 22: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
Chart 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 44
Chart 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 45
Chart 25: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 46
Chart 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront and Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 47
Chart 27: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 48
Chart 28: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 50
Chart 29: Pharmaceuticals and Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 52
Chart 30: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 54
Chart 31: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 56
Chart 32: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 58
Chart 33: Pharmaceuticals and Healthcare, Global, Musculoskeletal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 60
Chart 34: Pharmaceuticals and Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 62
Chart 35: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 64
Chart 36: Pharmaceuticals and Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 66
Chart 37: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 68
Chart 38: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 70
Chart 39: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 72
Chart 40: Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 74
Chart 41: Pharmaceuticals and Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Value (US$ m), Q3 2010 76
Chart 42: Pharmaceuticals and Healthcare, World Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q4 2009 - Q3 2010 77

Companies mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Top 50 Big Pharma Partnering and M&A Deal Trends

Top 50 Big Pharma Partnering and M&A Deal Trends

  • $ 3 295
  • Industry report
  • October 2014
  • by Currentpartnering

Summary The Top 50 Big Pharma Partnering and M&A Deal Trends report provides comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. ...

Upstream Oil and Gas Quarterly Deals Review, Q2 2014

Upstream Oil and Gas Quarterly Deals Review, Q2 2014

  • $ 1 500
  • Industry report
  • August 2014
  • by Global Data

Upstream Oil and Gas Quarterly Deals Review, Q2 2014 Summary GlobalData's “Upstream Oil and Gas Quarterly Deals Review, Q2 2014” report is an essential source of data and trend analysis on mergers ...

Merger and Acquisition Deals and Alliances of 2013

Merger and Acquisition Deals and Alliances of 2013

  • $ 1 495
  • Industry report
  • August 2014
  • by Currentpartnering

The Merger and Acquisition Deals and Alliances of 2013 provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies ...


1 Companies

Company Profiles


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.